Objective To inform selection of physical measures for studies of acute respiratory distress syndrome (ARDS) survivors within 12 months of ARDS.
INTRODUCTION
Survivors of acute respiratory distress syndrome (ARDS) frequently experience long-lasting physical impairments. 1 Clinical research in this patient population have used a wide range of performancebased and patient-reported physical measures, from evaluations of muscle mass and strength to the performance of activities of daily living (ADL). 2 This heterogeneity contributes to problems with interpreting and synthesising evidence across studies. 3 Bringing greater consistency to outcomes measurement is an important methodological challenge for critical care research. [3] [4] [5] Physical measures, particularly performancebased measures, such as manual muscle testing (MMT) and the 6 min walk test, have demonstrated reliability and validity in ARDS and other groups of intensive care unit (ICU) survivors. 6 7 In addition, inpatient measures of muscle strength were associated with mortality by 90 days 8 and 1 year 9 in critically ill patients. This literature is an important start for identifying core outcome measures. However, there is limited empirical research with head-to-head comparisons of physical measures to help researchers determine the optimal measures for evaluating postdischarge outcomes of ARDS survivors.
The current analysis will directly compare performance-based and patient-reported physical measures used in two different studies of ARDS survivors, based on independent associations with a range of patient-centred outcomes (ie, survival,
Key messages
What is the key question?
▸ Which physical measures are informative of current and future patient-centred outcomes in survivors during their first year of recovery after acute respiratory distress syndrome (ARDS)?
What is the bottom line?
▸ No measure of body functions and structures (eg, muscle strength) were associated with 12-month quality of life. Participation measures (eg, instrumental activities of daily living) are associated with quality of life and are recommended for future studies focused on evaluating and improving these outcomes in ARDS survivors.
Why read on?
▸ This study provides detailed empirical analyses to directly compare a wide range of physical status measures based on their associations with important patient-centred outcomes, including survival to 12 months, hospitalisation, being alive at home and health-related quality of life to help identify a core set of physical status measures for future studies of ARDS survivors.
hospitalisation, alive at home status and health-related quality of life (HRQL)), assessed concurrently and in the subsequent 6 months. Our goal is to help inform the selection of a minimum set of physical measures for future clinical research studies in the field. Among 6-month survivors of ARDS, we examined the associations of physical measures assessed at 6-month follow-up with 6-month and 12-month patient-centred outcomes. Physical measures are categorised according to the WHO's International Classification of Functioning, Disability and Health (ICF) framework to help evaluate how useful measures from different categories within the ICF framework are for inferring a range of patient-centred outcomes.
METHODS

Study design and data sources
Secondary analyses were performed using data from two studies, the ARDSNet Long-Term Outcome Study (ALTOS) and the Improving Care of Acute Lung Injury Patients (ICAP) study. 10 11 ALTOS included ARDS survivors from 12 hospitals across five study sites in the USA. 10 ALTOS subjects were recruited based on participation in at least one of three co-enrolling randomised trials, conducted by the National Heart, Lung and Blood Institute ARDS Network, evaluating aerosolised albuterol versus placebo (ALTA trial), 12 early versus delayed enteral feeding (EDEN trial) 13 and omega-3 fatty acid and antioxidant supplement versus placebo (OMEGA trial).
14 ICAP was a prospective cohort study that included ARDS survivors from 13 ICUs in four academic teaching hospitals in Baltimore, Maryland, USA. 11 Patients who survive to 6 months and have follow-up at 6 and 12 months are included in this analysis. Participants missing data on any 6-month physical measure were excluded from analysis. Analyses of 12-month patientcentred outcomes, excluding survival, are conducted among 12-month survivors.
Measures
Our analysis focused on physical measures and patient-centred outcomes that were available in the ALTOS and ICAP studies, and recommended or used in prior studies of physical outcomes in acute respiratory failure (ARF)/ARDS survivors. 1 2 15 Patient-centred outcomes A range of patient-centred outcomes were available and selected for inclusion in this analysis. These outcomes included death and any hospitalisation between 6 and 12 months' follow-up, as well as alive at home status at 6 and 12 months among those who resided at home at baseline (1=patient returned to living at home; 0=patient at another care facility or died between 6 and 12 months for the 12-month outcome) and HRQL at 6 and 12 months' follow-up. Data on survival (12-month), hospitalisation and alive at home status were obtained via patient or proxy report, as well as search of publicly available data sources (including the Social Security Death Index 16 ) for the mortality outcome. Patient-reported HRQL was evaluated using the Medical Outcomes Study Short-Form 36 survey V.2 (SF-36) 17 physical component score (PCS) and the EQ-5D-3L 18 19 utility score.
Physical measures
Physical measures, including performance-based and patientreported assessments, were evaluated at 6-month follow-up and categorised as body functions and structures, activity and participation according to the ICF framework. 20 Body functions and structures were measured by a range of clinical assessments performed in both studies. Pulmonary function was assessed using spirometry 21 and reported as per cent predicted FEV 1 using normative values. 22 In the study protocol for ICAP, spirometry was not performed at 6-month follow-up if already assessed at 3-month follow-up. Therefore, 3-month FEV 1 values were used for ICAP subjects missing 6-month values. Overall muscle strength was assessed by MMT and scored according to Medical Research Council criteria 23 24 (range, 0-60, with <48 indicating 'ICU-acquired weakness' 25 ) and by percentage of predicted value for hand grip strength. 26 Maximal inspiratory pressure (MIP), a measure of respiratory muscle strength, 27 28 and upper arm anthropometric assessment of per cent muscle, 29 30 which was calculated based on the mean of three triceps skinfold and three midarm circumference measurements, were also evaluated. Activity was represented by the 4 m gait speed (ALTOS only) and the 6 min walk test (6MWT, both studies). The 4 m gait speed was performed and scored according to published standards. 31 The 6MWT, as a percentage of the predicted value, was performed based on the American Thoracic Society (ATS) guidelines 32 with modest variation, including performing a single 6MWT at each followup (as done in prior ARDS research 1 ) and using the longest available distance (based on ATS guidelines 32 ) during home visits. Participation was represented by patient reports of ADLs 33 and Instrumental Activities of Daily Living (IADLs) 34 in the ICAP study, and the Functional Performance Inventory (FPI) 35 overall score in ALTOS.
Statistical analysis
Identical statistical analyses were performed for ALTOS and ICAP. For the bivariable analyses, data from the two studies were also combined to maximise sample size and statistical power.
Bivariable analyses
Associations between 6-month physical measures with 6-month and 12-month patient-centred outcomes were quantified using Pearson correlation coefficients for continuous outcomes (ie, SF-36 PCS, EQ-5D utility score) and unadjusted logistic regression analysis for binary outcomes (ie, survival to 12 months and alive at home status).
Multivariable analyses
We used multivariable regression models to test the independent associations of 6-month physical measures with each 6-month and 12-month patient-centred outcome. Linear regression models were used for SF-36 PCS and EQ-5D utility scores, and logistic regression models were used for survival, hospitalisation and alive at home status. These associations were examined separately for ICAP and ALTOS. All models included percentage predicted FEV 1 , percent muscle area, MIP, MMT, hand grip and 6MWT. In ICAP models, ADLs and IADLs were also included, while 4 m gait speed and FPI were added to ALTOS models. As a sensitivity analysis, we included baseline age, gender, race, body mass index, Charlson Comorbidity Index and Functional Comorbidity Index in these models to examine the robustness of the associations observed (data available upon request).
Variance inflation factors were computed for each multivariable regression model to assess for multicollinearity. 36 Loess graphs were inspected to confirm that linear models are appropriate for modelling the relationship between each physical assessment and patient-centred outcome. SAS V.9.4 was used for all analyses.
We also calculated standardised estimates for regression models to facilitate comparison of the strength of association across 6-month physical measures. Estimates for physical measures are standardised to the scale of the outcome in each model. These data are provided in an online supplement (see online supplementary tables A1-A4).
RESULTS
Patient characteristics were similar between ALTOS and ICAP in 6-month survivors (table 1), although ICAP had a higher proportion of black participants and longer lengths of stay, and a higher proportion of ALTOS patients had pneumonia. At 6 months, survivors from both studies had similar muscle strength, with ALTOS survivors having modestly higher FEV 1 per cent predicted, lower arm muscle area and higher per cent predicted 6MWT.
Survivors from both studies had comparable alive at home status and HRQL scores at both follow-ups, and relatively few deaths occurring between 6 and 12 months. A modestly larger proportion of ALTOS's 6-month survivors did not have a hospital readmission between 6 and 12 months.
Unadjusted associations with Concurrent (6-month) patient-centred outcomes
There were no statistically significant associations between being alive at home at 6 months and either body functions or structures measures in either study (table 2) Unadjusted associations with Future (12-month) patient-centred outcomes Among 12-month survivors, manual muscle test assessed at 6 months was significantly associated with SF-36 PCS at 12 months, but few other 6-month body functions and structures measures were consistently associated with 12-month outcomes across the two studies (table 3) . Activity measures (6MWT and 4 m gait speed) and participation measures (IADL and FPI) were consistently and positively associated with both HRQL outcomes in the following 6 months (all p<0.01). Significant correlation with survival status, hospitalisation and being alive at home in the subsequent 6 months was also observed with 6MWT, 4 m gait speed and IADL, but these associations were not consistently observed in both studies.
Independent associations with Concurrent (6-month) patient-centred outcomes
No body functions and structures measures at 6 months demonstrated independent associations with 6-month outcomes in both studies (table 4). The lack of consistent association of muscle strength measures (MMT, MIP and hand grip) with the SF-36 PCS, a physically oriented HRQL outcome, was particularly noteworthy. In contrast, the 6MWT was associated with the SF-36 PCS in both studies. Participation measures, IADL in ICAP and FPI in ALTOS, were associated with both HRQL outcomes. Multicollinearity was not observed across the ICF measures, including for the ADL and IADL measures, indicating distinct independent associations with the patient-centred outcomes for these two participation measures. With few exceptions, models including baseline variables produced comparable results.
Independent associations with Future 12-month patient-centred outcomes
None of the 6-month physical measures demonstrated significant independent association with survival or hospitalisation status in the next 6 months (table 5). FEV 1 was associated with being alive at home at 12 months, although the direction of the association differed in ICAP and ALTOS. Patient-reported participation measures, IADL in ICAP and FPI in ALTOS, were associated with both 12-month HRQL outcomes. Grip strength and 6MWT were also significantly associated with HRQL, but these associations were observed in only one of the two studies. Sensitivity analyses based on models with patient demographic and clinical variables were generally comparable.
DISCUSSION
Using two multisite, longitudinal clinical studies of ARDS survivors, our study provides empirical data among 6-month survivors on the associations of physical measures with a range of patient-centred outcomes (ie, survival, hospitalisation, alive at home and HRQL). Our focus on the performance of several widely used physical measures will be informative for current efforts to determine the core outcome sets 4 5 for this population.
Few measures of body functions and structures (eg, muscle area and three different measures of muscle strength) were independently associated with 6-month and 12-month outcomes. Furthermore, these associations were not consistently observed across the two studies. However, patient-reported participation measures, IADL and FPI, demonstrated independent associations with both HRQL outcomes at 6 and 12 months. Performance-based 6MWT was independently associated with the 6-month physically oriented SF-36 PCS outcome in both studies, but was only associated with the broader EQ-5D outcome in ICAP at 6 months. Significant independent associations of participation measures with future survival, hospitalisation and alive at home status were observed, although these associations were not consistently observed in both studies. †Alive at home outcome for 6 months (yes=1, no=0; combined--1, n=217, 95%; 0, n=11, 5%; ICAP--1, n=92, 97%; 0, n=3, 3%; ALTOS--1, n=125, 94%; 0, n=8, 6%). ‡0.11 m/s is an estimated MCID for the 4 m gait speed test based on prior study among patients with COPD. These results suggest that the participation measures we examined may be more useful than measures of body functions and structures (eg, MIP and MMT) for inferring concurrent 6-month and future 12-month HRQL. Specifically, for researchers interested in these patient-centred outcomes, our findings provide validity evidence supporting the use of the IADL or FPI patient-reported measures in future follow-up studies of ARDS survivors. The performance-based 6MWT may be useful for researchers more focused on the physical aspects of patient functioning and quality of life of ARDS survivors. The lack of significant independent associations for ADLs likely reflects that few patients experience impairments in these basic activities by 6-month follow-up. This low variation in ADLs across patients would limit the measure's associations with 6-month and 12-month patient-centred outcomes during the posthospitalisation recovery period.
Our findings may be helpful in future studies when limited time and resources warrant selection of a reduced battery of physical measures. It is important to note that while some measures, such as MIP or grip strength, were not independently associated with the patient-centred outcomes evaluated in our study, these measures can still provide valuable information on specific aspects of health targeted by the test, or possibly on patient-centred outcomes not examined in our study. The physical measures we recommended based on our empirical findings are intended to support current efforts to identify a minimum set of outcome measures that all studies in this field would use (ie, a 'core outcome set'). 5 For studies that aim to elucidate †Alive between 6 and 12 months (yes=1, no=0; combined--1, n=224, 96%; 0, n=9, 4%; ICAP--1, n=95, 96%; 0, n=4, 4%; ALTOS--1, n=129, 96%; 0, n=5, 4%). ‡No hospitalisation between 6 and 12 months (yes=1, no=0; combined--1, n=157, 76%; 0, n=49, 24%; ICAP--1, n=59, 73%; 0, n=22, 27%; ALTOS--1, n=98, 78%; 0, n=27, 22%). §Alive at home outcome for 12 months (yes=1, no=0; combined--1, n=208, 92%, 0, n=19, 8%; ICAP--1, n=88, 94%, 0, n=6, 6%; ALTOS--1, n=120, 90%; 0, n=13, 10%). ¶0.11 m/s is an estimated MCID for the 4 m gait speed test based on prior study among patients with COPD. '-', measure not available in dataset. *p≤0.05; **p≤0.01. †Alive at home outcome for 6 months (yes=1, no=0; ICAP--1, n=92, 97%, 0, n=3, 3%; ALTOS--1, n=125, 94%; 0, n=8, 6%). ‡0.11 m/s is an estimated MCID for the 4 m gait speed test based on prior study among patients with COPD. * p≤0.05; ** p≤0.01; '-', measure not available in dataset. †Alive between 6 and 12 months (yes=1, 0=no; ICAP--1, n=95, 96%; 0, n=4, 4%; ALTOS--1, n=129, 96%; 0, n=5, 4%). ‡No hospitalisation between 6 and 12 months (yes=1, 0=no; ICAP--1, n=59, 73%; 0, n=22, 27%; ALTOS--1, n=98, 78%; 0, n=27, 22%). §Alive at home outcome for 12 months (yes=1, 0=no; ICAP--1, n=88, 94%, 0, n=6, 6%; ALTOS--1, n=120, 90%; 0, n=13, 10% mechanism of action of a treatment, the inclusion of relevant physical and other mechanistic measures, as well as patientcentred outcomes, may be beneficial in understanding how the intervention exerts its effect. Whether a measure is informative of an outcome of interest is an important criterion during measure selection. However, other criteria, including feasibility, 37 are important to consider. Notably, performance-based activity measures have greater resource needs than self-reported participation measures. For instance, although our findings suggest that 6MWT and IADLs are both informative of patient HRQL, the 6MWT requires an in-person visit, basic equipment, appropriate physical surroundings and substantial time (at least 21 min for a single test given the required pretest rest break, 38 to perform the test). In contrast, the self-reported IADLs can be administered in 2-3 min via a survey or telephone interview. 39 For researchers interested in the patient-centred outcomes examined in our study, IADLs may be more suitable, particularly when in-person visits are not feasible, as in some national multicentre studies.
The general lack of association between measures of body functions and structures with the patient-centred outcomes evaluated in our study is an important finding. In prior studies, muscle weakness during hospitalisation has been associated with outpatient mortality. 8 9 However, our analyses were focused on selecting postdischarge physical measures, evaluated at 6-month follow-up, rather than in-hospital measures. This difference in findings at these time points suggests that the value of particular physical measures for inferring patient-centred outcomes may change over the course of a patient's recovery. 1 11 In addition, the patient-centred outcomes examined in our study are influenced by numerous health and environmental factors, particularly in the postdischarge period, which individual anatomical or physiological tests are unlikely to adequately reflect. It is important to note that while we observed that study measures within the same ICF domain (eg, body functions and structures) appear to demonstrate similar relationships, or lack of relationships, with outcomes, our findings are limited to the specific measures we examined. We cannot infer that comparable associations would be observed for other measures within the same ICF domain.
Our study also highlights challenges of using physical measures to infer some patient-centred outcomes in the posthospitalisation period. Few of the physical measures at 6 months demonstrated significant independent associations with survival, hospitalisation or alive at home status. The lack of association with survival may be due, in part, to relatively few deaths observed after 6-month follow-up in both studies. For the alive at home outcome, many non-physical issues including those described as 'environmental factors' in the ICF framework, 20 such as the availability of caregivers and home-based environmental adaptations (eg, installation of a ramp instead of stairs to enter the home setting), can influence this outcome.
This study has important strengths, including empirically evaluating the independent association of a wide range of physical measures with multiple patient-centred outcomes at 6 and 12 months. Many measures, especially those for body functions and structures, were available in two independent studies, allowing for comparison of findings across different samples of ARDS survivors. However, our study has several limitations. First, some activity and participation measures were included only in one study; hence, we could not evaluate generalisability of findings for these specific measures in both studies. Second, this study focused on 6-month survivors and the association of 6-month physical measures with 6-month and 12-month patient-centred outcomes in ARDS survivors in the USA; hence, the findings may not generalise to other patient populations, other time points in ARDS survivors' recovery or other patient-centred outcomes. Future research is needed to confirm our findings in other samples of survivors of critical illness, including non-US samples for international generalisability. Third, while we conducted sensitivity analysis of our findings by including baseline demographic and clinical variables in our multivariable analyses, we did not have the data to examine other potentially important variables such as pre-ICU functional status and HRQL. Therefore, we cannot determine the degree to which the observed associations between the physical measures and outcomes are influenced by a patient's preexisting health or functional status. Fourth, we used complete case analysis in our study, which could have introduced bias for our study estimates, as patients with complete data may be healthier in general. Finally, our study modelled the physical measures as continuous variables. Although the appropriateness of this modelling of the physical measures was confirmed for purposes of regression modelling, it was beyond the scope of this analysis to attempt to determine how to optimally model each physical measure with each patient-centred outcome examined in this study.
CONCLUSION
Bringing greater consistency to outcomes measurement is an important methodological challenge for critical care research. [3] [4] [5] For clinical researchers, selecting physical measures for studies of ARDS survivors over their first 12 months of recovery and participation measures such as IADLs will more closely reflect patient HRQL than measures of body functions and structures.
